Objective: The purpose of this study was to evaluate the trends in procedure volume, clinical sites of care, and Medicare expenditure for peripheral vascular interventions (PVIs) for lower extremity occlusive disease since the Centers for Medicare and Medicaid Services instituted reimbursement policy changes that broadened payment for procedures performed in physician-owned office-based laboratories (OBLs).
After years of rapid growth, today approximately 80% of peripheral vascular interventions (PVIs) are catheter based. 1, 2 The rapid growth in PVI utilization corresponds to a similarly dramatic increase in health care costs to treat peripheral arterial disease (PAD). In 2014, Medicare paid more than $22 billion to hospitals for medical claims with a diagnosis of PAD. 3 In a seminal publication by Jones et al, 4 the study authors showed that between 2006 and 2011, there had been a minimal increase in the annual rate of PVI. However, there was a dramatic shift in the location of these interventions from the inpatient to the outpatient setting. Specifically, they noted that there had been a marked reduction in the rate of PVI performed in the inpatient hospital setting, whereas there was a concomitant increase in the rate of PVI performed in the outpatient hospital and physician office settings. Moreover, the rate of atherectomy in outpatient hospital settings and office-based laboratories (OBLs) underwent the most significant change after the 2008 Medicare payment ruling was instituted. Compared with a twofold increase in the use of atherectomy in the outpatient hospital environment, there was a 50-fold increase in volume in OBLs, thereby offsetting any cost savings that had been accrued with regard to management of PVI in the outpatient setting.
With the introduction of new, bundled Current Procedural Terminology (CPT) codes, 2011 marked another important year for office-based PVI. Bundled codes reflect services that are reported together in at least 75% of cases. With these new CPT codes, the Centers for Medicare and Medicaid Services (CMS) assigned nonfacility practice expense relative value units (peRVUs) for all endovascular PVI codes, including balloon angioplasty, stent insertion, and atherectomy. 3 Hypothesizing that office-based PVI has continued to grow at a disproportionate rate relative to other sites of care, we decided to look at Medicare PVI utilization trends by setting since 2011, with particular attention to atherectomy. 
METHODS
The principal set of queries for this study was conducted by The Advisory Board Company, a Washington, D.C.-based research, technology, and consulting company. Medicare claims-based data sources included the hospital inpatient Standard Analytical File, which contains the final action fee-for-service claims data submitted by inpatient hospital providers; the hospital outpatient Standard Analytical File, which contains all institutional outpatient claims filed on the UB-04 form; and the physician/supplier Part B claims file, which contains a summary of all Part B carrier and durable medical equipment regional carrier claims processed. All data sources represent 100% of Medicare claims. Medicare fee schedule data were acquired from the publically available final ruling files accessible from the CMS website. We defined PVI using CPT codes 37220, 37221, and 37224 to 37231 and International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure codes 00.55, 17.56, 39.50, and 39.90. Surgical bypass was defined by ICD-9-CM procedure codes 39.25 and 39.29. The analyses conducted are not subject to Institutional Review Board approval, and patient informed consent was not required because this study does not satisfy the definition of "research" according to the U.S. Department of Health and Human Services regulation 45 CFR 46.102(d).
RESULTS
Between 2011 and 2014, endovascular PVI cases increased by 17%, whereas surgical bypass procedures declined by 5% (Fig 1) . Bypass represented 18% and 15% of cases in 2011 and 2014, respectively. The increasing share of endovascular cases was almost entirely a result of growth in PVI, as the volume of bypass has largely stabilized. Standing out in this analysis is the disproportionate growth of atherectomy in the management of PAD. In fact, most of the increase in PVI cases is attributable to atherectomy.
Focusing on atherectomy cases, the overall change in procedure volume was 60% between 2011 and 2014 (Fig 2) . However, the growth trajectory differed dramatically by clinical setting. Inpatient cases decreased by 11%, whereas ambulatory settings experienced increased volume. Physician OBLs accounted for the most pronounced change with a 298% increase in volume compared with the relatively modest 27% increase for hospital-based outpatient departments.
The percentage of atherectomy cases (whether standalone atherectomy or atherectomy with stenting) performed in OBLs increased substantially between 2011 and 2014 (Fig 3) . Across all vascular beds, the share of atherectomy performed in OBLs increased from 17% to 43%. By comparison, in 2014, just 20% of cases were performed in the hospital inpatient setting, and 37% of cases were performed in hospital outpatient departments. Therefore, OBLs are now the most common setting for atherectomy.
Besides atherectomy, other PVI cases, namely balloon angioplasty and stenting, have also migrated into the physician office setting; however, they have done so at a more modest rate (Fig 4) . Nonatherectomy PVI experienced a 94% growth rate in OBLs between 2011 and 2014. In 2014, the OBL PVI case mix was 67%, 18%, and 15% for atherectomy (including combined atherectomy and stent), balloon angioplasty, and stenting, respectively. For hospital outpatient departments, the mix was 27%, 33%, and 40%, respectively (Fig 5) . Among physician operators, in 2014, vascular surgery and cardiology represented the dominant specialties performing atherectomy in OBLs (Fig 6) . They held an almost equal share of femoral-popliteal cases, with each accounting for between 39% and 40% of cases. Radiology and general surgery were the other notable specialties but with far fewer cases. One prominent exception was tibial/peroneal atherectomy with stent, for which radiology's share was more pronounced at 27%. Table I shows total Medical expenditures for PVI cases performed in 2011 and 2014. Between 2011 and 2014, overall payment for PVIs increased by $446,000,000 (18%). Total hospital inpatient payment decreased modestly at À1%. In contrast, total hospital outpatient payment for PVI increased by 41%, and physician office-based payment grew by 258%. As a percentage of all Medicare expenditures for PVI, inpatient settings decreased from 76% to 64% (a 16% relative reduction), whereas hospital outpatient settings and physician office-based settings increased from 21% to 25% and 4% to 11% (20% and 203% relative increases), respectively.
DISCUSSION
The CMS instituted changes to the Outpatient Prospective Payment System and the Physician Fee Schedule in 2008, which laid the foundation for a shift of PVI cases to OBLs. CMS then introduced a new family of CPT codes for PVI in 2011 and assigned nonfacility peRVUs to each code. Importantly, the in-office reimbursement rate established for many of these services has been on par with or has exceeded hospital outpatient reimbursement since the introduction of these codes (Table II) . For instance, in 2016, CMS set the baseline physician office reimbursement for peRVUs for femoral-popliteal atherectomy (CPT 37225) at $10,723, which is 112% of the baseline hospital outpatient payment rate of $9542.
Compared with atherectomy, reimbursement for nonatherectomy PVI is lower, and the peRVU amounts tend to be significantly less than the hospital outpatient amounts. This lends credence to the hypothesis that reimbursement has influenced setting of care and revascularization strategy decisions. Specifically, a higher and more generous reimbursement rate for office-based atherectomy (compared with hospital outpatient) has contributed to the disproportionate growth for this service in OBLs.
In a paper by Jones et al 4 from Duke University, the study authors showed that following changes in the Outpatient Prospective Payment System between 2008 and 2011, there was a major shift in PVI, particularly atherectomy, to hospital outpatient and OBL care settings. Our analysis of Medicare data from 2011 to 2014 reveals that this trend has continued with an 11% decline in inpatient volume, a 27% increase in outpatient hospital volume, and a 298% increase in OBL cases. In other words, a >10-fold increase in volume in OBLs was noted compared with the hospital outpatient setting. Furthermore, our study has revealed a marked change in total Medicare expenditures by setting that coincided with and was consistent with this shift in procedure setting. Whereas advocates for office-based PVI have reported that OBLs offer some advantages over hospital outpatient departments, such as improved patient access and care coordination, 5, 6 the high rate of atherectomy in OBLs may be a cause for concern. For comparison, atherectomy is used in approximately one-third of all endovascular PVIs in the United States and just 4% in western Europe and even less in Canada, Japan, and Latin America. 3, 7 This discrepancy is especially noteworthy because published trials and practice guidelines do not indicate broad superiority of atherectomy over alternative treatments. For instance, the Cochrane Peripheral Vascular Diseases Group Trials Search Coordinator examined randomized controlled trials comparing atherectomy and balloon angioplasty with or without stenting. 8 Four trials were included in this analysis representing 220 patients treated for claudication or critical limb ischemia; 108 patients were treated with atherectomy and 102 were treated with angioplasty. The group found that studies performed to date have not been adequately powered and are nonblinded, and they exhibit a high risk of selection and reporting bias. The review concluded that there was no primary patency benefit of atherectomy over angioplasty. There was a higher incidence of distal embolization with atherectomy and a higher incidence of dissection with angioplasty, but the results could not be pooled for significance. No statistically significant difference in adverse events, such as target lesion revascularization and above-knee amputation, was noted between the two modalities of treatment. The reviewers concluded that for patients with PAD amenable to treatment with angioplasty with or without stent, angioplasty should remain the "gold standard." The Determination of Effectiveness of the SilverHawk Peripheral Plaque Excision System (SilverHawk device) for the Treatment of Infrainguinal Vessels/Lower Extremities (DEFINITIVE LE) trial is a large observational study that has shown promising 12-month patency data that compare favorably with results obtained using secondgeneration nitinol stents; however, it does not reach level 1 data. [9] [10] [11] [12] Practice guidelines like the recent Society for Cardiovascular Angiography and Interventions expert consensus statements for infrapopliteal and femoralpopliteal intervention appropriate use point to the dearth of comparative evidence to support the use of atherectomy devices in these clinical scenarios. 13, 14 Study limitations. This analysis included only patients enrolled in Medicare and may not be generalizable to other populations of patients. Furthermore, analyses did not attempt to characterize patients by disease complexity and other factors that may have influenced the selection of revascularization options. Finally, we did not assess the short-or long-term clinical outcomes of patients treated by setting or revascularization strategy. Therefore, we cannot draw conclusions about the clinical merits or limitations of one treatment pathway over another.
CONCLUSIONS
The migration of revascularization procedures for lower extremity peripheral arterial occlusive disease continues from the inpatient to the outpatient setting and especially to OBLs. Increased use of atherectomy in all segments of the lower extremity arterial system has been observed, particularly in OBLs, without substantial evidence in the literature of increased efficacy compared with standard angioplasty with or without stenting. Generous Medicare reimbursement for in-office atherectomy procedures is likely contributing to the volume shifts observed.
